United Capital Financial Advisers, LLC Cti Biopharma Corp Transaction History

United Capital Financial Advisers, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$3.81 - $5.26 $97,364 - $134,419	-25,555 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$2.7 - $4.06 $74,576 - $112,141	-27,621 Reduced 51.94%	25,555 $100,000
Q4 2017 Feb 13, 2018	BUY	$2.47 - $3.34 $1,370 - $1,853	555 Added 1.05%	53,176 $143,000
Q2 2017 Aug 14, 2017	BUY	N/A	52,621	52,621 $157,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.